Another very exciting, very loaded GU ’19, ASCO GU 2019. In kidney cancer specifically a lot of new data presented. In the oral session, in the rapid fire session, in the poster sessions, specifically the combinations are coming to renal cell cancer. Two studies that met their primary endpoint, axitinib and pembrolizumab, that have a progression free survival response rate and an overall survival benefit against standard sunitinib in first line advanced clear cell RCC. Similarly axitinib and a PD-L1 inhibitor, avelumab, had a response rate and PFS benefit with a pending data analysis for overall survival against sunitinib.

We have data also in non-clear cell RCC – MET inhibitors, savolitinib plus a PD-L1 inhibitor in non-clear cell RCC presented by Dr Powles as well as a combination of atezolizumab and bevacizumab with Dr McKay showing a response rate up to 30% or a bit higher. That combination we know its activity in clear cell RCC. Dr McDermott also presented data, again in non-clear cell RCC, in pembrolizumab single agent, response rate around 25%. I invite you to look at the details to see what type of non-clear cell RCC may respond. As you know, non-clear cell RCC encompasses many sub-histologies if you want.

Also data from Dr Rini, another new TKI we’re familiar with from previous trials, tivozanib, now in third line. Tivozanib versus sorafenib, the study met its primary endpoint, there has been a press release around it and Dr Rini presented that data.

In the poster session and other sessions there’s a lot actually of correlatives and a lot of biomarker data that was presented that is interesting. Again, it’s a very, very loaded GU ’19; it’s hard now not to go to each of these meetings, the ASCO meeting, the ASCO GU meeting, new information every time and hopefully you’re able to digest that information perhaps on your trip back to where you come from. Thank you.